- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Chronic kidney disease
- Meeting Date: November 2021
- Public Summary Document (PSD) November 2021 PBAC Meeting - (PDF 1843KB)
- Public Summary Document (PSD) November 2021 PBAC Meeting - (Word 357KB)
Dapagliflozin – November 2021
Dapagliflozin: Tablet 10 mg; Forxiga®
Last updated
4 March 2022